Primary systemic therapy in HER2-positive operable breast cancer using trastuzumab and chemotherapy: efficacy data, cardiotoxicity and long-term follow-up in 142 patients diagnosed from 2005 to 2016 at a single institution

Silvia Antolín,1 Benigno Acea,2 Luis Albaina,2 Ángel Concha,3 Paz Santiago,3 Tomás García-Caballero,4 Joaquín J Mosquera,5 José Ramón Varela,5 Rafaela Soler,5 Lourdes Calvo1 1Medical Oncology Department, Breast Unit, A Coru...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Antolín S, Acea B, Albaina L, Concha Á, Santiago P, García-Caballero T, Mosquera JJ, Varela JR, Soler R, Calvo L
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2018
Materias:	Neoadjuvant therapy HER2-positive breast cancer pathologic complete response cardiotoxicity survival Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/baccee9a46d042eca38ea148ccbfb013
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:baccee9a46d042eca38ea148ccbfb013
record_format	dspace
spelling	oai:doaj.org-article:baccee9a46d042eca38ea148ccbfb0132021-12-02T07:00:29ZPrimary systemic therapy in HER2-positive operable breast cancer using trastuzumab and chemotherapy: efficacy data, cardiotoxicity and long-term follow-up in 142 patients diagnosed from 2005 to 2016 at a single institution1179-1314https://doaj.org/article/baccee9a46d042eca38ea148ccbfb0132018-12-01T00:00:00Zhttps://www.dovepress.com/primary-systemic-therapy-in-her2-positive-operable-breast-cancer-using-peer-reviewed-article-BCTThttps://doaj.org/toc/1179-1314Silvia Antolín,1 Benigno Acea,2 Luis Albaina,2 Ángel Concha,3 Paz Santiago,3 Tomás García-Caballero,4 Joaquín J Mosquera,5 José Ramón Varela,5 Rafaela Soler,5 Lourdes Calvo1 1Medical Oncology Department, Breast Unit, A Coruña University Hospital, A Coruña, Spain; 2Surgery Department, Breast Unit, A Coruña University Hospital, A Coruña, Spain; 3Anatomic Pathology Department, Breast Unit, A Coruña University Hospital, A Coruña, Spain; 4Department of Morphological Sciences, University of Santiago de Compostela, Santiago de Compostela, A Coruña, Spain; 5Radiology Department, Breast Unit, A Coruña University Hospital, A Coruña, Spain Objective: The aim of this study was to evaluate the efficacy, cardiotoxicity profile and long-term benefits of neoadjuvant therapy in human epidermal growth factor receptor 2-positive operable breast cancer patients. Patients and methods: A total of 142 patients diagnosed from 2005 to 2016 were included in the study. The treatment consisted of a sequential regimen of taxanes and anthracyclines plus trastuzumab. The clinical and pathological responses were evaluated and correlated with clinical and biological factors. The cardiotoxicity profile and long-term benefits were analyzed. Results: The median age was 49 years, and 4%, 69% and 27% of patients had stage I, II and III breast cancer, respectively, while 10% had inflammatory breast cancer at diagnosis. Hormone receptor (HR) status was negative in 43%, and 62% had grade III breast cancer. The clinical complete response rate was 49% and 63% as assessed using ultrasound and magnetic resonance imaging, respectively, and this allowed a high rate of conservative surgery (66%). The pathological complete response (pCR) rate was 52%, and it was higher in HR-negative (64%) patients than in HR-positive (41%) patients and in grade III breast cancer (53%) patients than in grade I–II breast cancer (45%) patients. Patients who achieved pCR had longer disease-free survival and a trend toward improved overall survival. A total of 2% of patients showed a 10% decrease in left ventricular ejection fraction to <50% during treatment. All patients except one recovered after discontinuation of trastuzumab. Conclusion: A sequential regimen of taxanes and anthracyclines plus trastuzumab was effective, with high pCR rates and long-term benefit, and had a very good cardiotoxicity profile. Keywords: neoadjuvant therapy, HER2-positive breast cancer, pathological complete response, cardiotoxicity, survivalAntolín SAcea BAlbaina LConcha ÁSantiago PGarcía-Caballero TMosquera JJVarela JRSoler RCalvo LDove Medical PressarticleNeoadjuvant therapyHER2-positive breast cancerpathologic complete responsecardiotoxicitysurvivalNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENBreast Cancer: Targets and Therapy, Vol Volume 11, Pp 29-42 (2018)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neoadjuvant therapy HER2-positive breast cancer pathologic complete response cardiotoxicity survival Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Neoadjuvant therapy HER2-positive breast cancer pathologic complete response cardiotoxicity survival Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Antolín S Acea B Albaina L Concha Á Santiago P García-Caballero T Mosquera JJ Varela JR Soler R Calvo L Primary systemic therapy in HER2-positive operable breast cancer using trastuzumab and chemotherapy: efficacy data, cardiotoxicity and long-term follow-up in 142 patients diagnosed from 2005 to 2016 at a single institution
description	Silvia Antolín,1 Benigno Acea,2 Luis Albaina,2 Ángel Concha,3 Paz Santiago,3 Tomás García-Caballero,4 Joaquín J Mosquera,5 José Ramón Varela,5 Rafaela Soler,5 Lourdes Calvo1 1Medical Oncology Department, Breast Unit, A Coruña University Hospital, A Coruña, Spain; 2Surgery Department, Breast Unit, A Coruña University Hospital, A Coruña, Spain; 3Anatomic Pathology Department, Breast Unit, A Coruña University Hospital, A Coruña, Spain; 4Department of Morphological Sciences, University of Santiago de Compostela, Santiago de Compostela, A Coruña, Spain; 5Radiology Department, Breast Unit, A Coruña University Hospital, A Coruña, Spain Objective: The aim of this study was to evaluate the efficacy, cardiotoxicity profile and long-term benefits of neoadjuvant therapy in human epidermal growth factor receptor 2-positive operable breast cancer patients. Patients and methods: A total of 142 patients diagnosed from 2005 to 2016 were included in the study. The treatment consisted of a sequential regimen of taxanes and anthracyclines plus trastuzumab. The clinical and pathological responses were evaluated and correlated with clinical and biological factors. The cardiotoxicity profile and long-term benefits were analyzed. Results: The median age was 49 years, and 4%, 69% and 27% of patients had stage I, II and III breast cancer, respectively, while 10% had inflammatory breast cancer at diagnosis. Hormone receptor (HR) status was negative in 43%, and 62% had grade III breast cancer. The clinical complete response rate was 49% and 63% as assessed using ultrasound and magnetic resonance imaging, respectively, and this allowed a high rate of conservative surgery (66%). The pathological complete response (pCR) rate was 52%, and it was higher in HR-negative (64%) patients than in HR-positive (41%) patients and in grade III breast cancer (53%) patients than in grade I–II breast cancer (45%) patients. Patients who achieved pCR had longer disease-free survival and a trend toward improved overall survival. A total of 2% of patients showed a 10% decrease in left ventricular ejection fraction to <50% during treatment. All patients except one recovered after discontinuation of trastuzumab. Conclusion: A sequential regimen of taxanes and anthracyclines plus trastuzumab was effective, with high pCR rates and long-term benefit, and had a very good cardiotoxicity profile. Keywords: neoadjuvant therapy, HER2-positive breast cancer, pathological complete response, cardiotoxicity, survival
format	article
author	Antolín S Acea B Albaina L Concha Á Santiago P García-Caballero T Mosquera JJ Varela JR Soler R Calvo L
author_facet	Antolín S Acea B Albaina L Concha Á Santiago P García-Caballero T Mosquera JJ Varela JR Soler R Calvo L
author_sort	Antolín S
title	Primary systemic therapy in HER2-positive operable breast cancer using trastuzumab and chemotherapy: efficacy data, cardiotoxicity and long-term follow-up in 142 patients diagnosed from 2005 to 2016 at a single institution
title_short	Primary systemic therapy in HER2-positive operable breast cancer using trastuzumab and chemotherapy: efficacy data, cardiotoxicity and long-term follow-up in 142 patients diagnosed from 2005 to 2016 at a single institution
title_full	Primary systemic therapy in HER2-positive operable breast cancer using trastuzumab and chemotherapy: efficacy data, cardiotoxicity and long-term follow-up in 142 patients diagnosed from 2005 to 2016 at a single institution
title_fullStr	Primary systemic therapy in HER2-positive operable breast cancer using trastuzumab and chemotherapy: efficacy data, cardiotoxicity and long-term follow-up in 142 patients diagnosed from 2005 to 2016 at a single institution
title_full_unstemmed	Primary systemic therapy in HER2-positive operable breast cancer using trastuzumab and chemotherapy: efficacy data, cardiotoxicity and long-term follow-up in 142 patients diagnosed from 2005 to 2016 at a single institution
title_sort	primary systemic therapy in her2-positive operable breast cancer using trastuzumab and chemotherapy: efficacy data, cardiotoxicity and long-term follow-up in 142 patients diagnosed from 2005 to 2016 at a single institution
publisher	Dove Medical Press
publishDate	2018
url	https://doaj.org/article/baccee9a46d042eca38ea148ccbfb013
work_keys_str_mv	AT antolins primarysystemictherapyinher2positiveoperablebreastcancerusingtrastuzumabandchemotherapyefficacydatacardiotoxicityandlongtermfollowupin142patientsdiagnosedfrom2005to2016atasingleinstitution AT aceab primarysystemictherapyinher2positiveoperablebreastcancerusingtrastuzumabandchemotherapyefficacydatacardiotoxicityandlongtermfollowupin142patientsdiagnosedfrom2005to2016atasingleinstitution AT albainal primarysystemictherapyinher2positiveoperablebreastcancerusingtrastuzumabandchemotherapyefficacydatacardiotoxicityandlongtermfollowupin142patientsdiagnosedfrom2005to2016atasingleinstitution AT conchaa primarysystemictherapyinher2positiveoperablebreastcancerusingtrastuzumabandchemotherapyefficacydatacardiotoxicityandlongtermfollowupin142patientsdiagnosedfrom2005to2016atasingleinstitution AT santiagop primarysystemictherapyinher2positiveoperablebreastcancerusingtrastuzumabandchemotherapyefficacydatacardiotoxicityandlongtermfollowupin142patientsdiagnosedfrom2005to2016atasingleinstitution AT garciacaballerot primarysystemictherapyinher2positiveoperablebreastcancerusingtrastuzumabandchemotherapyefficacydatacardiotoxicityandlongtermfollowupin142patientsdiagnosedfrom2005to2016atasingleinstitution AT mosquerajj primarysystemictherapyinher2positiveoperablebreastcancerusingtrastuzumabandchemotherapyefficacydatacardiotoxicityandlongtermfollowupin142patientsdiagnosedfrom2005to2016atasingleinstitution AT varelajr primarysystemictherapyinher2positiveoperablebreastcancerusingtrastuzumabandchemotherapyefficacydatacardiotoxicityandlongtermfollowupin142patientsdiagnosedfrom2005to2016atasingleinstitution AT solerr primarysystemictherapyinher2positiveoperablebreastcancerusingtrastuzumabandchemotherapyefficacydatacardiotoxicityandlongtermfollowupin142patientsdiagnosedfrom2005to2016atasingleinstitution AT calvol primarysystemictherapyinher2positiveoperablebreastcancerusingtrastuzumabandchemotherapyefficacydatacardiotoxicityandlongtermfollowupin142patientsdiagnosedfrom2005to2016atasingleinstitution
_version_	1718399657786212352

Primary systemic therapy in HER2-positive operable breast cancer using trastuzumab and chemotherapy: efficacy data, cardiotoxicity and long-term follow-up in 142 patients diagnosed from 2005 to 2016 at a single institution

Ejemplares similares